South Korea · Delayed Price · Currency is KRW NGeneBio Statistics
Total Valuation
NGeneBio has a market cap or net worth of KRW 13.62 billion. The enterprise value is 43.00 billion.
| Market Cap | 13.62B |
| Enterprise Value | 43.00B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NGeneBio has 8.94 million shares outstanding. The number of shares has increased by 45.58% in one year.
| Current Share Class | 8.94M |
| Shares Outstanding | 8.94M |
| Shares Change (YoY) | +45.58% |
| Shares Change (QoQ) | +3.15% |
| Owned by Insiders (%) | 7.50% |
| Owned by Institutions (%) | 0.51% |
| Float | 6.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.33 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.45, with a Debt / Equity ratio of 1.95.
| Current Ratio | 0.45 |
| Quick Ratio | 0.39 |
| Debt / Equity | 1.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.15 |
| Interest Coverage | -1.72 |
Financial Efficiency
Return on equity (ROE) is -26.81% and return on invested capital (ROIC) is -9.84%.
| Return on Equity (ROE) | -26.81% |
| Return on Assets (ROA) | -7.73% |
| Return on Invested Capital (ROIC) | -9.84% |
| Return on Capital Employed (ROCE) | -31.68% |
| Weighted Average Cost of Capital (WACC) | 8.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.82 |
| Inventory Turnover | 26.03 |
Taxes
| Income Tax | -965.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.56% in the last 52 weeks. The beta is 0.91, so NGeneBio's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -69.56% |
| 50-Day Moving Average | 2,048.50 |
| 200-Day Moving Average | 4,264.21 |
| Relative Strength Index (RSI) | 40.13 |
| Average Volume (20 Days) | 269,778 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NGeneBio had revenue of KRW 41.80 billion and -5.04 billion in losses. Loss per share was -587.47.
| Revenue | 41.80B |
| Gross Profit | 5.78B |
| Operating Income | -6.30B |
| Pretax Income | -5.84B |
| Net Income | -5.04B |
| EBITDA | -4.86B |
| EBIT | -6.30B |
| Loss Per Share | -587.47 |
Balance Sheet
The company has 6.55 billion in cash and 36.39 billion in debt, with a net cash position of -29.84 billion or -3,339.27 per share.
| Cash & Cash Equivalents | 6.55B |
| Total Debt | 36.39B |
| Net Cash | -29.84B |
| Net Cash Per Share | -3,339.27 |
| Equity (Book Value) | 18.69B |
| Book Value Per Share | 2,141.41 |
| Working Capital | -28.02B |
Cash Flow
In the last 12 months, operating cash flow was -5.13 billion and capital expenditures -26.63 billion, giving a free cash flow of -31.76 billion.
| Operating Cash Flow | -5.13B |
| Capital Expenditures | -26.63B |
| Depreciation & Amortization | 1.44B |
| Net Borrowing | 24.61B |
| Free Cash Flow | -31.76B |
| FCF Per Share | -3,553.83 |
Margins
Gross margin is 13.83%, with operating and profit margins of -15.08% and -12.06%.
| Gross Margin | 13.83% |
| Operating Margin | -15.08% |
| Pretax Margin | -13.96% |
| Profit Margin | -12.06% |
| EBITDA Margin | -11.63% |
| EBIT Margin | -15.08% |
| FCF Margin | n/a |
Dividends & Yields
NGeneBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.58% |
| Shareholder Yield | -45.58% |
| Earnings Yield | -37.02% |
| FCF Yield | -233.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 13, 2026. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Jul 13, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
NGeneBio has an Altman Z-Score of -0.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.91 |
| Piotroski F-Score | 1 |